New Indicator of Human Malignant Tumour
Author Information
Author(s): S. Metcalfe, J. Milner, R.J. Svvennsen
Primary Institution: Addenbrooke's Hospital, University of Cambridge
Hypothesis
Can the B5 monoclonal antibody serve as an indirect marker for malignant tumours?
Conclusion
The B5 antibody effectively distinguishes between cancer patients and healthy individuals, indicating its potential as a tumour marker.
Supporting Evidence
- Over 80% of cancer patients tested positive for B5.
- Less than 20% of healthy individuals tested positive for B5.
- B5 positivity was observed in various types of cancer, including those affecting the central nervous system.
Takeaway
Scientists found a new way to tell if someone has cancer by looking at their blood with a special test called B5.
Methodology
The study involved haemagglutination tests using the B5 monoclonal antibody on blood samples from cancer patients and controls.
Potential Biases
Potential for false positives in normal individuals.
Limitations
Insufficient data to determine if B5 can differentiate between malignant and benign tumours.
Participant Demographics
Included 386 cancer patients and 247 healthy controls.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website